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EDITORIAL COMMENT
T-Wave Alternans and Serious
Ventricular Arrhythmias:
A Tale of Two T-Waves*
Hal V. Barron, MD, FACC
South San Francisco, California
Sudden cardiac death (SCD) is one of the most important
public health problems in the world today and is the leading
cause of mortality in developing countries. Serious ventric-
ular arrhythmias are the most common mechanism respon-
sible for SCD. Thus, in order to prevent SCD, it is crucial
to have effective diagnostic tools to identify patients at risk
for these arrhythmias. Unfortunately, despite multiple trials
in acute myocardial infarction (AMI) and congestive heart
failure, our understanding of how to identify those patients
at highest risk for SCD and how to best prevent this
devastating occurrence remains incomplete.
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To date, various noninvasive tests such as the left ven-
tricular ejection fraction (LVEF) (1,2), signal-averaged
electrocardiography (SAECG) (3,4), ventricular ectopy de-
termined by Holter monitoring, autonomic tone as mea-
sured by heart rate variability and baroreflex sensitivity (5–7)
and abnormalities of ventricular repolarization as reflected
by QT dispersion (8) have been proposed as modalities to
identify patients at high risk for developing ventricular
arrhythmias. However, the predictive value of each of these
tests is low, with the majority of patients with a positive test
never developing a life-threatening arrhythmia. Further-
more, with recent studies confirming the benefit of implant-
able cardioverter-defibrillators (ICDs) in preventing SCD
(9,10), and the high cost associated with this therapy, our
need for a diagnostic test or set of tests to identify those
patients who will most likely benefit from ICD therapy is
essential.
While beat-to-beat alterations in the electrical amplitude
of the electrocardiogram (ECG) have been appreciated for
almost a century (11), it has only been in the last 25 years
that this phenomenon has been linked to SCD. By exam-
ining the specific fluctuations in the morphology of the T
wave during alternating beats, numerous investigators have
demonstrated that T-wave or repolarization alternans is
associated with the development of ventricular arrhythmias
in animal models. These findings, coupled with the obser-
vations that T-wave alternans (TWA) precedes the devel-
opment of ventricular arrhythmias in patients undergoing
coronary angioplasty (12), with Printzmetal’s angina (13),
long QT syndrome (14,15), AMI and electrolyte derange-
ments (16), have prompted several investigators to explore
whether TWA could be used as a clinical tool to identify
patients at high risk for developing SCD. In the pursuit of
this goal, Smith et al. (17) and others (18) developed
sophisticated signal-processing techniques and found that
subtle alterations in T-wave morphology, which are not
apparent on the surface ECG, are reflective of physiologi-
cally important abnormalities in repolarization.
This technique, referred to as microvolt-level electrical
alternans of the T wave or microscopic TWA, has been the
focus of several clinical studies. The original studies required
the use of atrial pacing to unmask the microvolt alternans
signal. Using this method, Rosenbaum et al. (19) examined
83 patients referred for diagnostic electrophysiologic testing
and found that TWA was a significant and independent
predictor of inducible arrhythmias on electrophysiologic
testing (sensitivity 81%, specificity 84%; RR 5 5.2). Of the
66 patients followed up to 20 months, TWA was essentially
as useful as electrophysiologic testing in predicting
arrhythmia-free survival. Hohnloser et al. (20) and Estes et
al. (21) subsequently found that the assessment of microvolt
TWA could be simplified by substituting atrial pacing with
exercise to accelerate the heart rate to the optimal level.
With this advance, TWA could be assessed completely
noninvasively. Using this noninvasive approach, Ikeda et al.
(22) prospectively assessed TWA, SAECG and LVEF in
102 patients after AMI. The sensitivity and negative pre-
dictive value of TWA was very high (93% and 98%,
respectively), suggesting that such a test could be used as a
screening test. However, the positive predictive value was
only 28%, suggesting that TWA had many of the limita-
tions of the previously identified risk stratification tests.
Importantly though, patients with a positive study on both
TWA and SAECG had a 50% event rate, suggesting that
by combining these two tests one could identify a very high
risk group.
The present study by Gold et al. (23) included 313
patients, making it the largest prospective study of patients
scheduled to undergo electrophysiologic testing. The pri-
mary end point of the study was the occurrence of ventric-
ular tachyarrhythmic events, as defined prospectively by
SCD, sustained ventricular tachycardia, ventricular fibrilla-
tion or appropriate implantable defibrillator therapy for
ventricular tachycardia or cardiac arrest. Overall, the test
performed very well, and in a multivariate analysis in which
11 clinical parameters were examined, only TWA and
electrophysiologic testing were independent predictors of
these events. Although it was not stated in the article, the
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sensitivity and specificity for this outcome were 88% and
64%, respectively (personal communication, Dr. Gold),
suggesting again that TWA may be an ideal screening test.
However, the probability of experiencing an event at 400
days in patients with a positive TWA test was 19%, versus
only 2% in patients with a negative TWA test. In other
words, 81% of the TWA-positive patients remained event-
free. Patients with both a positive TWA and SAECG had
an event rate of 32.3%, versus ,3% for all other patients
with a determinant test. Thus, TWA appears to be a very
useful noninvasive tool to identify patients at risk for
ventricular tachyarrhythmic events (high sensitivity and
high negative predictive value), and the combination of
SAECG and TWA can be used to identify patients at high
risk for these events.
Some issues and limitations of this study should be
highlighted. First, while the combination of SAECG and
TWA appears to be a reasonable way of identifying high
risk patients, it is important to point out that of the 313
patients in the study, only 155 patients had a determinant
SAECG and TWA. Of these 155 patients, only 10 expe-
rienced a ventricular tachyarrhythmic event. The authors
state that overall there were 27 patients who experienced a
ventricular tachyarrythmic event. Thus, of the 158 patients
with an indeterminate test result on either TWA or
SAECG (and thus who were not apparently included in the
analysis), 17 experienced an adverse event. This suggests
that the majority of patients who experienced a ventricular
tachyarrhythmic event did not have a determinate SAECG
or TWA, limiting the utility of this combined testing
approach. Further, it appears that those patients with an
indeterminate test might have actually been relatively high
risk as well. This may not be surprising, because the main
reason for having an indeterminate TWA was inability to
exercise to a target heart rate of 100 or the presence of
frequent ventricular ectopy, both of which might be ex-
pected to be associated with increased risk of SVE and
death. Similarly, the most common reason for having an
indeterminate SAECG was the presence of a wide QRS
complex, which is also known to be associated with a worse
prognosis. Thus, it would be interesting to explore whether
patients with an indeterminate test are actually at increased
risk compared with patients who have a negative test and
whether this information could be incorporated into the
testing algorithm to enable TWA testing to be applicable to
more patients.
Another limitation of this study is that there was no
mention of concomitant medications during the follow-up
period. It is possible that this could have affected the results
of the study. Beta-blockers are clearly very effective antiar-
rhythmic agents and prevent the development of SCD (24),
but despite this, they are significantly underutilized (25). It
is unfortunate that most studies investigating the utility of
risk stratification tests fail to have the majority of eligible
study patients on beta-blocker therapy. Whether TWA
would have been as useful a test had all eligible patients
received beta-blocker therapy is unknown. If the beneficial
effect of beta-blocker therapy is in part related to its effect on
reducing repolarization heterogeneity, then one might hy-
pothesize that such an interaction might exist. It is impor-
tant to explore this issue further in future studies.
Finally, the study by Gold et al. (23) examined only the
SAECG, TWA, LVEF and an electrophysiology study.
Recent studies have suggested that baroreflex sensitivity
testing and heart rate variability are two very important risk
stratification techniques and may have a role in identifying
patients at risk for SCD. Whether the combination of
TWA and autonomic tone testing would have been sub-
stantially superior to TWA and SAECG is yet to be
determined and could be the focus of future studies.
Despite these caveats, the article by Gold et al. (23)
provides an important contribution to the literature and
adds to our understanding of TWA. As always, several
important questions remain unanswered. The most impor-
tant question is: How should these noninvasive tests be used
clinically? It is tempting to propose that TWA and SAECG
could replace invasive testing to identify patients at high risk
for SCD who might benefit from ICD therapy. This should
be the focus of future clinical research, but we simply do not
have enough data today to support this approach. It is
important to remember that the Antiarrhythmic Versus
Implantable Defibrillator trial (9) and Multicenter Auto-
matic Defibrillator Implantation Trial (10), which demon-
strated superiority of automatic implanted cardiac defibril-
lator therapy over antiarrhythmic drug therapy, required
spontaneous sustained ventricular arrhythmias and inducible
ventricular arrhythmias, respectively, for inclusion into the
trial. The Coronary Artery Bypass Graft-Patch trial (26),
which did not show a benefit of ICD therapy, used SAECG
to identify high risk patients. Thus, it is possible that not all
patients at high risk for death from SCD will benefit from
ICD therapy and that the modality chosen to identify high
risk is very important.
In the year 2000, it is clear that we have effective devices
to decrease SCD, but unfortunately no ideal test to identify
those patients who need them. Charles Dickens might have
described this ironic situation with the following words, “It
was the best of times, it was the worst of times, it was the
age of wisdom, it was the age of foolishness . . . we had
everything before us, we had nothing before us . . . ” Hope-
fully, the Tale of Two T Waves will evolve, and the
continued pursuit for the perfect test or tests to identify
patients at risk for a ventricular tachyarrhythmic event will
be fruitful. Through such endeavors, I am confident that we
will someday be able to treat more effectively the most
devastating clinical problem in cardiology today—sudden
cardiac death.
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